Entrada Therapeutics, Inc. (TRDA): Total Liabilities
$71.25M
As of 2025-12-31
$65.47M
As of 2026-06-30
+21.7%
3-year compound annual growth
+84.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $71.25M | -27.0% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $97.64M | -57.0% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $226.83M | +474.2% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $39.50M | +455.2% | 2024-03-13, Balance as of period end |
| 2021-12-31 | $7.12M | +111.8% | 2023-03-06, Balance as of period end |
| 2020-12-31 | $3.36M | n/a | 2022-03-15, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $71.25M | -27.0% |
| Celularity Inc (CELU) | 2025-12-31 | $145.39M | +17.4% |
| Alumis Inc. (ALMS) | 2025-12-31 | $110.64M | +36.8% |
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $15.78M | +7.4% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $85.85M | -19.9% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $306.60M | -7.0% |
| Verastem, Inc. (VSTM) | 2025-12-31 | $189.25M | +45.1% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | $62.93M | +21.4% |
| Scynexis Inc (SCYX) | 2025-12-31 | $9.65M | -72.9% |
Compare TRDA, CELU, ALMS, CUE side by side · Screen every company in Pharmaceutical Preparations ↗